Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Pancreatic Neoplasms 35Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 15Lung Neoplasms 13Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Neoplasms 10Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Head and Neck Neoplasms 4Carcinoma, Pancreatic Ductal 4Stomach Neoplasms 3Neoplasms by Site 3Gastrointestinal Neoplasms 3Carcinoma 3Adenocarcinoma 3Vaccinia 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms by Histologic Type 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thymoma 1

Interventions

Docetaxel 2Cisplatin 2130-nm albumin-bound paclitaxel 2taxane 1liposomal doxorubicin 1durvalumab 1cemiplimab 1atezolizumab 1Pemetrexed 1Paclitaxel 1Nivolumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Biosimilar Pharmaceuticals 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vaccinia × 130-nm albumin-bound paclitaxel × 90 days × Clear all
NCT06463665 2026-06-04

VIRO-25

Genelux Corporation

Phase 2 Recruiting
142 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡